Show simple item record

dc.contributor.authorYin, Lina
dc.contributor.authorHu, Qingzhong
dc.contributor.authorHartmann, Rolf W
dc.date.accessioned2013-02-21T08:04:32Z
dc.date.available2013-02-21T08:04:32Z
dc.date.issued2012
dc.identifier.citation3-Pyridyl substituted aliphatic cycles as CYP11B2 inhibitors: aromaticity abolishment of the core significantly increased selectivity over CYP1A2. 2012, 7 (11):e48048 PLoS ONEen_GB
dc.identifier.issn1932-6203
dc.identifier.pmid23133610
dc.identifier.doi10.1371/journal.pone.0048048
dc.identifier.urihttp://hdl.handle.net/10033/269912
dc.description.abstractAldosterone synthase (CYP11B2) is a promising therapeutic target for the treatment of cardiovascular diseases related to abnormally high aldosterone levels. On the basis of our previously identified lead compounds I-III, a series of 3-pyridinyl substituted aliphatic cycles were designed, synthesized and tested as CYP11B2 inhibitors. Aromaticity abolishment of the core was successfully applied to overcome the undesired CYP1A2 inhibition. This study resulted in a series of potent and selective CYP11B2 inhibitors, with compound 12 (IC(50) = 21 nM, SF = 50) as the most promising one, which shows no inhibition toward CYP1A2 at 2 µM. The design conception demonstrated in this study can be helpful in the optimization of CYP inhibitor drugs regarding CYP1A2 selectivity.
dc.language.isoenen
dc.rightsArchived with thanks to PloS oneen_GB
dc.title3-Pyridyl substituted aliphatic cycles as CYP11B2 inhibitors: aromaticity abolishment of the core significantly increased selectivity over CYP1A2.en
dc.typeArticleen
dc.contributor.departmentPharmaceutical and Medicinal Chemistry, Saarland University & Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Saarbrücken, Germany.en_GB
dc.identifier.journalPloS oneen_GB
refterms.dateFOA2018-06-12T17:49:31Z
html.description.abstractAldosterone synthase (CYP11B2) is a promising therapeutic target for the treatment of cardiovascular diseases related to abnormally high aldosterone levels. On the basis of our previously identified lead compounds I-III, a series of 3-pyridinyl substituted aliphatic cycles were designed, synthesized and tested as CYP11B2 inhibitors. Aromaticity abolishment of the core was successfully applied to overcome the undesired CYP1A2 inhibition. This study resulted in a series of potent and selective CYP11B2 inhibitors, with compound 12 (IC(50) = 21 nM, SF = 50) as the most promising one, which shows no inhibition toward CYP1A2 at 2 µM. The design conception demonstrated in this study can be helpful in the optimization of CYP inhibitor drugs regarding CYP1A2 selectivity.


Files in this item

Thumbnail
Name:
yin et al_final.pdf
Size:
590.2Kb
Format:
PDF
Description:
Open Access publication

This item appears in the following Collection(s)

Show simple item record